A new study concludes that the Bayesian adaptive dosing strategy significantly improves the accuracy of achieving the target busulfan AUC in patients undergoing HCT.
Published in British Journal of Clinical Pharmacology.
https://t.co/b2cgPoxQic | #Bayesian#AUC#HCT#Busulfan
This recent study addresses the question, can we extract unrecognized #SADRs with known #PK mechanisms from biomedical literature using natural language processing tools & validate DDIs-SADR signals through multi-source EHR databases?
https://t.co/a9E2pJhJA5 | @ASCPT_ClinPharm
A new study evaluates whether the pediatric selexipag dosage recommendation, based on the #PopPK model for adults, achieves similar drug exposures in #PediatricPulmonaryArterialHypertension (PAH) patients: https://t.co/F9btWGl5Dr
A new study examines the link between #vancomycin supratherapeutic dosing & #AKI using a novel correlation factor equation.
Key finding: All AKIs occurred with AUC <600—pharmacists should assess other AKI causes.
Author: Yazan Batarseh, @HMCHospital:
https://t.co/yzMI3htK0M
The goal of this study was to leverage ensemble learning approaches to develop physiological aging measures from point-of-care #biomarkers.
Published in Pharmacometrics & Systems Pharmacology.
➡ https://t.co/SCw8HS4Db2 | #PhysiologicalAge#PrecisionMedicine#PrecisionDosing
In this editorial, scientists call upon the #ClinicalPharmacology & translational science community to collaborate across sectors & disciplines to be able to collectively transform the landscape of rare & neglected diseases.
https://t.co/MnGaSs7bfx #RareDisease#ClinicalResearch
A new study demonstrates that the selection of an appropriate adult reference population is important for pediatric PK exposure matching & pediatric dose selection, especially for a drug substantially eliminated through renal excretion: https://t.co/755KhZf3y3 | #Pharmacokinetics
Over 380K vancomycin treatment courses were used to evaluate the predictive performance of various vancomycin PK models across diverse age and BMI categories. Learn how to apply these findings to your patient. https://t.co/L6KMmeP8CJ @InsightRX@Steph_lnfection@idpharmresearch
Stephanie Hughes, PharmD, BCIDP, joins Dr. Michael Rybak on the @ACCP Journal Podcast to discuss her study on #vancomycin#PKModels in diverse age & BMI groups.
Learn how to apply insights from 380K+ treatment courses to your patients.
🎧 Listen now: https://t.co/TU2ZCSJ51e
This study compares GFR models to the Mech-KiM model with hypothetical drugs and metronidazole (96% reabsorption).
Dive into the findings in CPT: Pharmacometrics & Systems Pharmacology: https://t.co/z33cbWQYxr
#Pharmacometrics#Pharmacology#Pharmacokinetics#PBPK
The InsightRX Team would like to wish you a safe and Happy Thanksgiving! We are grateful for all the clinicians working today and every day to keep their patients safe.
#HappyThanksgiving#Grateful#Thankful
This recent study investigated which factors are associated with receiving pharmacogenetically targeted drugs & estimated cost-effects of untargeted pre-emptive #pharmacogenetic panel testing with #CostBenefitModel. https://t.co/6MfMofL1UL @UniTurku@helsinkiuni@ASCPT_ClinPharm
A new study addresses if a #PBPK model coupled with a relative transcriptomics approach can predict local anifrolumab tissue concentrations & receptor occupancy, to guide dose selection for phase III anifrolumab studies in new indications: https://t.co/4DC7e2sGzB